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Summary
Survivin is a member of the inhibitor of apoptosis (IAP) family. It is also involved in the regulation of cell division. 
Survivin is widely expressed in foetal tissues and in human cancers, but generally not in normal adult tissue. This study 
examined the expression of survivin protein in a series of 50 cases of invasive primary breast carcinoma. Our study com-
prised 50 cases of breast cancer, 10 of each immunophenotype. All tumours were diagnosed as invasive ductal carcinoma 
(Not Otherwise Specifi ed, NOS). Formalin-fi xed, paraffi  n-embedded tissue sections were immunostained for survivin. 
 Survivin immunoreactivity was evaluated as follows: 0(0-5% positive cells); 1(5–20%); 2(21–50%); 3(51–75%); 4(>76%) with 
cutoff  value of 20% that was established as a positive result. Immunohistochemical analysis showed positive expression for 
survivin in 18 of 50 cases (36%) of breast carcinomas of TNM stages I to III. In previous studies, there was signifi cant rela-
tionship between survivin expression and negative prognostic factors like larger tumour size, higher histologic grade and 
negative hormonal status. What we should emphasize in our study is the correlation between HER2 positive tumours and 
survivin expression (P=0.007) and strong association of survivin expression in cytoplasm in HER2 positive tumours as a 
predictor of unfavourable outcome. Further larger studies are needed in future to explore and explain the facts about 
 survivin and its connection with breast cancer.
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SURVIVIN I PROLIFERATIVNI INDEKS Ki67 U RAKU DOJKE
Sažetak
Survivin je protein koji je član obitelji inhibitora apoptoze, a uključen je i u regulaciju stanične diobe. Široko je raspro-
stranjen u fetalnim tkivima i ljudskim tumorima, ali se u pravilu ne javlja u normalnim odraslim tkivima. Studijom smo 
 ispitali izražajnost survivina u seriji od 50 slučajeva invazivnog primarnog karcinoma dojke. Obrađeno je 50 slučajeva, po 
10 od svakog imunofenotipa. Svi tumori su dijagnosticirani kao invazivni duktalni karcinom (NOS). Dijelovi tumorskog 
tkiva su fi ksirani u formalinu i uklopljeni u parafi nske kocke te je napravljena imunohistokemijska obrada na survivin. 
Imunoreaktivnost survivina je procijenjena: 0 (0-5% pozitivnih tumorskih stanica); 1 (5-20%); 2 (21-50%); 3 (51-75%)i 4 
(> 76%) uz graničnu vrijednost od 20%, koja je ustanovljena kao pozitivan rezultat. Imunohistokemijska analiza pokazala je 
pozitivnu izraženost survivina u 18 slučajeva (36%) TNM stadija I do III. U prethodnim studijama vidljiva je značajna pove-
zanost izraženosti survivina i negativnih prognostičkih čimbenika kao što su veličina tumora, visoki histološki gradus i 
negativni hormonalni status. Treba naglasiti da je prediktor nepovoljnog ishoda pozitivna korelacija HER2 pozitivnih tumo-
ra i izražajnosti survivina u njihovoj citoplazmi (P=0.007) Potrebne su buduće studije koje će istražiti i objasniti činjenice 
vezane uz survivin i njegov odnos s karcinomom dojke.




Apoptosis is the process of programmed cell 
death where senescent or damaged cells that are 
beyond repair are eliminated. It is a cascade of 
molecular events regulated by proteins that pro-
mote or prevent cell death. It is believed to be an 
important mechanism by which therapeutic che-
motherapy and radiation therapy destroy cancer 
cells (1). Aberrant inhibition of apoptosis inter-
feres with normal cell regulation and promotes 
tumour development (2).
Survivin is an anti-apoptotic protein that is 
overexpressed in most human cancers. Survivin 
regulates the G2/M phase of the cell cycle by as-
sociating with mitotic spindle microtubules, and 
it directly inhibits caspase-3 and caspase-7 activ-
ity. During tumorogenesis, survivin expression 
is inversely correlated with apoptosis inhibition 
and positively correlated with proliferation and 
angiogenesis (3).
Survivin mRNA was found to be diff usely 
expressed during foetal development, but it was 
generally not found in normal adult tissues. Sur-
vivin is also overexpressed in most human can-
cers including bladder (4), blood (5,6), colon (7,8), 
liver (9), brain (10,11,12), lung (13), pancreas (14), 
prostate (15), and kidney (16). In the majority of 
cancers studied to date, survivin is associated 
with poor prognosis. Clinicopathological investi-
gations on the role of survivin in breast cancer fo-
cusing on its importance as a prognostic factor 
have been limited (1). In this article, we investi-
gated the prevalence and cellular localization of 
survivin in a series of 50 primary breast cancers, 




In our research, we observed immunohisto-
chemical results of survivin and the relation be-
tween survivin and proliferative index Ki67 in 50 
cases of breast cancer in accordance with immun-
ophenotype by St. Galen (2015 god.). Our study 
comprised 50 cases of breast cancer, 10 of each im-
munophenotype. Patients age was between 29 and 
84 years at the time of diagnosis. The size of the 
tumours varied between 0.5 and 6 cm. The TNM 
stage of tumors was as follows: Twenty-four tu-
mours were T1 (less than 2 cm in diameter), 22 tu-
mours were T2 (2-5 cm), 2 tumours were T3 (larger 
than 5 cm in diameter) and 2 tumours were T4 (in-
volvement of epidermis). All tumours were diag-
nosed as invasive ductal carcinoma (NOS). Five 
tumours were grade 1, 17 tumours were grade 2 
and 28 tumours were grade 3.
Immunohistochemistry
Formalin-fi xed, paraffi  n-embedded tissue sec-
tions were immunostained for survivin. Sections 3 
mm thick were cut, dewaxed in xylene and rehy-
drated in alcohol. Prior to immunohistochemical 
staining sections were blocked for endogenous ac-
tivity with 3% H2O2. Antigen retrieval was carried 
in citrate buff er, pH 6.0 in wather bath for 40 min-
utes. The sections were then incubated overnight at 
4 oC with mouse monoclonal antibody against sur-
vivin protein (clone 12C4, Dako, Carpinteria, USA) 
at dilution of 1:100 for all cases. Sections were 
washed in PBS to remove unbound antisera. Bound 
antibody was detected using En Vision detection 
kit for 60 minutes (En Vision Flex, kat.no. K8010, 
Dako, Glostrup, Denmark) and visualised with 
DAB as a chromogen (10 minutes). Slides were then 
lightly counterstained with haematoxylin.
Evaluation of immunohistochemistry results
Survivin immunoreactivity was evaluated 
semiquantitatively according to the previous stu-
dies (1). Nuclear and cytoplasmic tumour cell im-
munoreactivities were separately assessed at 40 
magnifi cation, and were given an arbitrary score: 
0(0-5% positive cells); 1(5–20%); 2(21–50%); 3(51–
75%); 4(>76%). A cutoff  value of 20% was estab-
lished as a positive result. Invasive tumours with 
a score of 0 or 1 were considered negative. The re-
sults were separately analysed and statistically 
calculated (1).
We found that of those specimens that were 
survivin positive, 3 of 18 expressed survivin in the 
nuclear region of the tumour cell. In 12 specimens, 
the reactivity was confi ned to the cytoplasm, and 
in 6 it was present in both nucleus and cytoplasm 
as seen in Figure (1). Considering small number of 
positive cases and relatively small sample, nuclear 




Figure 1. Immunohistochemical reaction of survivin in nucleus 
and cytoplasm in breast cancer tumour cells.(IHCx40)
Table 1.
TUMOUR IMMUNOPHENOTYPE: LUMINAL A
LUMINAL A
AGE SIZE (cm) GRADE T SURVIVIN Ki67
40 2.2x1,5x1.2 1 2 neg 12,3
52 1.3x0.7x0.4 1 1c neg 7
73 1.2x0.9x0.8 2 1c 50% n 12
71 0.9x0.6x0.5 1 1b neg 7,2
49 1x1x1.2 2 1c 80% nc 5
67 1.1x1x1 2 1c 60% n 17,9
46 1.7x1.1x1.5 2 1c neg 16
73 3x2.2x2.3 2 2 neg 17
50 2.1x1.7x1.2 1 2 neg 12
65 1.2x0.7x1.2 1 1c neg 8,6
T – tumor stage; Ki67 – proliferative index; c- cytoplasm; n - nucleus
Table 2.
TUMOUR IMMUNOPHENOTYPE: LUMINAL B, HER-2 NEGATIVE
LUMINAL B HER2 NEG.
AGE SIZE (cm) GRADE T SURVIVIN Ki67
78 3x3x1.7 3 2 25% c 24,5
49 3.5x2.4x3 3 2 neg 90
38 1.2x0.9x0.8 3 1c neg 25,6
56 1.5x1.3x1.3 2 1c neg 35
66 3.2x3x3 2 2 90% c 28,5
74 6x4x2.7 3 4b 40% c 24,5
58 1.1x0.6x0.6 2 1c neg 34
74 2.2x2.2x1.5 2 2 neg 43
77 4x2x3.5 3 2 neg 33
63 0.9x0.4x0.5 2 1b neg 23
T – tumor stage; Ki67 – proliferative index; c- cytoplasm; n - nucleus
Table 3.
TUMOUR IMMUNOPHENOTYPE: LUMINAL B, HER-2 POSITIVE
LUMINAL B HER2 POSITIVE
AGE SIZE (cm) GRADE T SURVIVIN Ki67
36 1.5X1,2X1 2 1c neg. 31
71 0.6 2 1b 20% n 31
67 2.5x1.7x1.3 2 2 neg. 45
64 3.5x2.8x1.8 3 2
30% n 50% 
c 14,3
60 1.8x1.3x1,.5 2 1c 70% nc 17
65 2x2x1 3 1c neg. 47
62 1.3 3 1c neg. 18
40 1.8x1 3 1c 90% c 24,2
72 2.5x2.5x2 2 2 neg. 9,4
79 2.2x1.8x1.5 3 2 neg. 31,7
T – tumor stage; Ki67 – proliferative index; c- cytoplasm; n - nucleus
Statistical analysis
Statistical analysis was done using chi-squared 
test. P < 0.05 was considered to be statistically sig-
nifi cant.
RESULTS
Immunohistochemical analysis showed posi-
tive expression for survivin in 18 of 50 cases (36%) 
of breast carcinomas of TNM stages I to III. In con-
trast, no expression of survivin in adjacent normal 
tissue was detected. (fi gure 1.)
When we consider luminal A type of tu-
mours, our results are negative for survivin in 
70% of the cases (7 of 10) and those that are posi-
tive show nuclear positivity only (Table 1).
In luminal B type of tumours, 70% of the cas-
es (7 of 10) were negative for survivin, and those 
that were positive were grade II-III and were larg-
er (T2-T4b). (Table 2).
In luminal B, HER2positive tumours result 
for survivin was negative in 6 of 10 tumours (60%) 
and positive in 4 of 10 tumours (40%). Those cases 
that were positive for survivin were grade II-III 
and T1b-T2, and showed no relation with prolif-
erative index Ki67 (Table 3).
Triple negative tumours were survivin nega-
tive in 80% of the cases (8 of 10), and positivity in 
nucleus and cytoplasm was found in cases of 
small-sized tumours (T1a and T1b). (Table 4).
According to our results survivin is diff usely 
expressed in Her-2 positive tumours in 9 of 10 
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 cases (90%) and shows 30-90% cytoplasmic posi-
tivity.
There is no correlation between survivin and 
Ki67 proliferative index, because according to ta-
ble 5., there is a large extent between 13.3 and 
50.6% which are all survivin positive.
DISCUSSION
The role of survivin has been studied in many 
cancers but litt le has been reported about the role 
of survivin in breast cancer (18). High expression 
of survivin is associated with poor prognosis in 
most human cancers as well as in breast carcino-
ma (19). There are some studies that show that as-
sociation of survivin with prognosis is ambiguous 
(20), some studies that report survivin prognosti-
cally irrelevant (21) and some studies that connect 
survivin with good prognosis (1,22).
Survivin is a member of the inhibitor of apop-
tosis (IAP) family that plays important role in cell 
proliferation and carcinogenesis in many organs 
in human. In previous studies, there was signifi -
cant relationship between survivin expression 
and negative prognostic factors like larger tumour 
size, higher histologic grade and negative hor-
monal status (1,17,18). The positivity of survivin 
can be nuclear or cytoplasmic. It is important to 
emphasize that nuclear positivity goes along with 
bett er outcome, and that cytoplasmic positivity is 
an indicator of adverse prognosis (1,22,23).
Statistical analysis in our study showed that 
there was complete consistency with expression of 
survivin and tumour size over 5 cm in diameter, 
although there was no consistency with survivin 
expression and tumour size under 5 cm (P=0,597). 
When we consider tumour grade, there are some 
signifi cant results if we separate grade 1 in one 
group and put grade 2 and grade 3 in another 
group. The latt er group is accordant with survivin 
expression (P=0.0449). We did not fi nd signifi cant 
relationship between survivin expression and age 
of the patients (P=0.492) or survivin expression 
and proliferative index Ki67 (P=0.603). There was 
no strong correlation between survivin expression 
and positive oestrogen receptors (P=0.128). What 
we should emphasize in our study is the correla-
tion between HER2 positive tumours and survivin 
expression (P=0.007).
Table 5.
TUMOUR IMMUNOPHENOTYPE: HER-2 POSITIVE
HER2 POSITIVE
AGE SIZE (cm) GRADE T SURVIVIN Ki67
77 5.5X3X3.5 3 3 50% c 37
53 1.5X1.2X1.4 3 1c 80% nc 17,2
69 1.9X1.3X1.5 3 1c 30% c 32
49 1.9X1.8X1.5 3 1c 90% c 45
51 4X2.6X1.6 3 2 30% c 35,2
83 2.2X1.2X1.5 3 2 70% c 40
37 2.5X2X1 3 2 80% c 50,6
73 2.5X2X1 3 2 80% c 43
74 2.1X1.8X0.9 2 2 60% c 13,3
29 2.5X1.9X1.5 3 2 neg. 38,2
T – tumor stage; Ki67 – proliferative index; c- cytoplasm; n - nucleus
Figure 2. Chart representing number of survivin positive and 
survivin negative tumours regarding immunophenotype. HER-
2 positive tumors show positivity in 90% of all cases.
Table 4.
TUMOUR IMMUNOPHENOTYPE: TRIPLE NEGATIVE
TRIPLE NEGATIVE
AGE SIZE (cm) GRADE T SURVIVIN Ki67
65 4.2X3.8X3.5 3 2 neg. 70
68 1.3X1.1X0.9 3 1c neg. 70
58 1.9X1.5X1.5 3 1c neg. 64
39 4X2.3X3.9 3 3 neg. 90
68 2.5X2X2.5 3 2 neg. 47
43 3.5X2.5X3 3 2 neg. 90
84 0.9X0.8X0.5 2 1b 30% nc 14,8
41 0.5X0.5X0.4 3 1a 30% nc 55
75 4X3X3.5 3 4 neg. 33
76 4X3X2 3 2 neg. 80
T – tumor stage; Ki67 – proliferative index; c- cytoplasm; n - nucleus
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What we can interpretate in our research is 
that survivin is not expressed in luminal A or lu-
minal B types of tumours, or its expression in nu-
cleus is an indicator of bett er prognosis which is 
consistent with previous studies (18). Strong as-
sociation of survivin expression in cytoplasm in 
HER2 positive tumours is a predictor of unfavour-
able outcome (18). What stays unclear in our study 
is lack of survivin expression in triple negative 
tumour types, or positivity in small sized tumours 
which does not comply with results in previous 
studies (18).
CONCLUSION
In conclusion, survivin expression is related to 
adverse prognostic parameters in breast cancer as 
well as in other human cancers. This is a prelimi-
nary study and further larger studies are needed in 
future to explore and explain the facts about sur-
vivin and its connection with breast cancer.
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